申请人:Pfizer Inc.
公开号:US04188391A1
公开(公告)日:1980-02-12
6,7-Dialkoxy-4-[4-(substituted)piperidino]quinazolines wherein the 4-substituent is -(CHR.sup.1).sub.m -Z wherein R.sup.1 is hydrogen or lower alkyl; m is 1 or 2, with the proviso that when m is 2, each R.sup.1 can be the same or different; Z is -N(R.sup.2)COR.sup.3, -OCONR.sup.4 R.sup.5, N(R.sup.2)SO.sub.2 R.sup.3 or -N(R.sup.2)CONR.sup.4 R.sup.5 wherein R.sup.2 is hydrogen or lower alkyl; R.sup.3 is lower alkyl, benzyl or phenyl; and each of R.sup.4 and R.sup.5 is hydrogen or is selected from group R.sup.3 ; and methods for their preparation. The compounds are phosphodiesterase inhibitors and cardiac stimulants.
6,7-二烷氧基-4-[4-(取代)piperidino]喹唑啉,其中4-取代基为-(CHR.sup.1).sub.m -Z,其中R.sup.1为氢或较低的烷基;m为1或2,但当m为2时,每个R.sup.1可以相同也可以不同;Z为-N(R.sup.2)COR.sup.3,-OCONR.sup.4 R.sup.5,N(R.sup.2)SO.sub.2 R.sup.3或-N(R.sup.2)CONR.sup.4 R.sup.5,其中R.sup.2为氢或较低的烷基;R.sup.3为较低的烷基,苄基或苯基;R.sup.4和R.sup.5中的每一个为氢或从R.sup.3组中选择;以及它们的制备方法。这些化合物是磷酸二酯酶抑制剂和心脏兴奋剂。